Joseph Schwartz, an analyst from Leerink Partners, reiterated the Hold rating on PTC Therapeutics (PTCT – Research Report). The ...

Good afternoon, ladies and gentlemen, and thank you for standing by, and welcome to today's PTC 2024 fourth-quarter conference call. (Operator Instructions) I would now like to turn the call over to ...

PTC Therapeutics ( (PTCT) ) has released its Q3 earnings. Here is a breakdown of the information PTC Therapeutics presented to its investors.

Industrial software maker PTC forecast first-quarter revenue below estimates on Wednesday, signaling continued weakness in ...

PTC's core business segments — CAD (Computer ... Increasing recurring revenues as well as focus on go-to-market strategies are positives. Apart from these, the shift toward a subscription ...

PTC Stock Performance Shares of PTC opened at $198.04 on Thursday. The company’s 50 day moving average price is $179.50 and its 200 day moving average price is $178.13. PTC Inc. has a 52 week ...

PTC Inc. operates in the industrial design end markets, offering solutions that support growth and free cash flow (FCF) generation. The company's core focus areas include Product Lifecycle ...

The biopharmaceutical company posted revenue of $196.8 million in the period, also beating Street forecasts. Five analysts surveyed by Zacks expected $173.5 million. PTC Therapeutics expects full-year ...

Berenberg downgraded PTC (PTC, Financials) to hold from buy on Friday, citing a lack of stabilization in key markets that have continued to experience macroeconomic challenges, particularly aerospace, ...

Q4 2024 Earnings Conference Call November 6, 2024 5:00 PM ETCompany ParticipantsMatt Shimao - Head of Investor RelationsNeil Barua ...